Lancet Gastroenterol Hepatol. 2020 Jun;5(6):561-581. doi: 10.1016/S2468-1253(19)30408-X. Epub 2020 Mar 13.
Gastro-oesophageal reflux disease is a common chronic ailment that causes uncomfortable symptoms and increases the risk of oesophageal adenocarcinoma. We aimed to report the burden of gastro-oesophageal reflux disease in 195 countries and territories between 1990 and 2017, using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017.
We did a systematic review to identify measurements of the prevalence of gastro-oesophageal reflux disease in geographically defined populations worldwide between 1990 and 2017. These estimates were analysed with DisMod-MR, a Bayesian mixed-effects meta-regression tool that incorporates predictive covariates and adjustments for differences in study design in a geographical cascade of models. Fitted values for broader geographical units inform prior distributions for finer geographical units. Prevalence was estimated for 195 countries and territories. Reports of the frequency and severity of symptoms among individuals with gastro-oesophageal reflux disease were used to estimate the prevalence of cases with no, mild to moderate, or severe to very severe symptoms at a given time; these estimates were multiplied by disability weights to estimate years lived with disability (YLD).
Data to estimate gastro-oesophageal reflux disease burden were scant, totalling 144 location-years (unique measurements from a year and location, regardless of whether a study reported them alongside measurements for other locations or years) of prevalence data. These came from six (86%) of seven GBD super-regions, 11 (52%) of 21 GBD regions, and 39 (20%) of 195 countries and territories. Mean estimates of age-standardised prevalence for all locations in 2017 ranged from 4408 cases per 100 000 population to 14 035 cases per 100 000 population. Age-standardised prevalence was highest (>11 000 cases per 100 000 population) in the USA, Italy, Greece, New Zealand, and several countries in Latin America and the Caribbean, north Africa and the Middle East, and eastern Europe; it was lowest (<7000 cases per 100 000 population) in the high-income Asia Pacific, east Asia, Iceland, France, Denmark, and Switzerland. Global prevalence peaked at ages 75-79 years, at 18 820 (95% uncertainty interval [95% UI] 13 770-24 000) cases per 100 000 population. Global age-standardised prevalence was stable between 1990 and 2017 (8791 [95% UI 7772-9834] cases per 100 000 population in 1990 and 8819 [7781-9863] cases per 100 000 population in 2017, percentage change 0·3% [-0·3 to 0·9]), but all-age prevalence increased by 18·1% (15·6-20·4) between 1990 and 2017, from 7859 (6905-8851) cases per 100 000 population in 1990 to 9283 (8189-10 400) cases per 100 000 population in 2017. YLDs increased by 67·1% (95% UI 63·5-70·3) between 1990 and 2017, from 3·60 million (1·93-6·12) in 1990 to 6·01 million (3·22-10·19) in 2017.
Gastro-oesophageal reflux disease is common worldwide, although less so in much of eastern Asia. The stability of our global age-standardised prevalence estimates over time suggests that the epidemiology of the disease has not changed, but the estimates of all-age prevalence and YLDs, which increased between 1990 and 2017, suggest that the burden of gastro-oesophageal reflux disease is nonetheless increasing as a result of ageing and population growth.
Bill & Melinda Gates Foundation.
胃食管反流病是一种常见的慢性疾病,会引起不适症状,并增加食管腺癌的风险。我们旨在报告 1990 年至 2017 年间 195 个国家和地区胃食管反流病的负担,使用来自 2017 年全球疾病、伤害和风险因素研究(GBD)的数据。
我们进行了系统评价,以确定 1990 年至 2017 年间全球地理定义人群中胃食管反流病的患病率测量值。使用 DisMod-MR 对这些估计值进行分析,DisMod-MR 是一种贝叶斯混合效应荟萃回归工具,它结合了预测性协变量,并对地理级联模型中的研究设计差异进行了调整。更广泛的地理单位的拟合值为更精细的地理单位提供了先验分布。为 195 个国家和地区估计了患病率。使用胃食管反流病患者的症状频率和严重程度报告来估计特定时间内无症状、轻度至中度或重度至非常严重症状的病例的患病率;这些估计值乘以残疾权重,以估计残疾年限(YLD)。
用于估计胃食管反流病负担的数据很少,总计 144 个位置年(来自一年和一个位置的唯一测量值,无论研究是否与其他位置或年份的测量值一起报告)的患病率数据。这些数据来自七个 GBD 超级区域中的六个(86%)、21 个 GBD 区域中的 11 个(52%)和 195 个国家和地区中的 39 个(20%)。2017 年所有地点年龄标准化患病率的平均估计值范围为每 100000 人口 4408 例至 14035 例。年龄标准化患病率最高(>11000 例/100000 人口)的地区是美国、意大利、希腊、新西兰以及拉丁美洲和加勒比、北非和中东以及东欧的几个国家;在高收入亚太地区、东亚、冰岛、法国、丹麦和瑞士,患病率最低(<7000 例/100000 人口)。全球患病率在 75-79 岁年龄组达到峰值,为每 100000 人口 18200(95%置信区间[95%UI]为 13770-24000)例。全球年龄标准化患病率在 1990 年至 2017 年期间保持稳定(1990 年每 100000 人口 8791 例(95%UI 为 7772-9834),2017 年每 100000 人口 8819 例(7781-9863),百分比变化 0.3%[-0.3 至 0.9]),但所有年龄组的患病率在 1990 年至 2017 年间增加了 18.1%(15.6-20.4),从 1990 年的每 100000 人口 7859 例(6905-8851)增加到 2017 年的每 100000 人口 9283 例(8189-10400)。残疾年限(YLDs)在 1990 年至 2017 年间增加了 67.1%(95%UI 为 63.5-70.3),从 1990 年的 360 万(193-612)增加到 2017 年的 601 万(322-1019)。
胃食管反流病在全球范围内很常见,尽管在东亚的大部分地区发病率较低。我们全球年龄标准化患病率估计值的稳定性表明,该疾病的流行病学没有改变,但所有年龄组的患病率和 YLDs 的估计值在 1990 年至 2017 年间有所增加,表明胃食管反流病的负担仍在增加,这是由于人口老龄化和人口增长所致。
比尔及梅琳达·盖茨基金会。